← Back to headlines
Sarepta outlines $1.2B–$1.4B 2026 revenue target as ELEVIDYS educational push ramps up
Sarepta Therapeutics projects a 2026 revenue target of $1.2 billion to $1.4 billion, driven by an intensified educational push for its drug ELEVIDYS.
26 Feb, 01:28 — 26 Feb, 01:28
Sources
Showing 1 of 1 sources
